Researchers Submit Patent Application, "T Cell Receptors Directed Against Bob1 And Uses Thereof", for Approval (USPTO 20240009235).
In: Cancer Gene Therapy Week, 2024-01-29, S. 153-153
serialPeriodical
Zugriff:
Inventors FALKENBURG and HEEMSKERK have submitted a patent application for a new invention related to T cell receptors and their potential use in treating B cell malignancies and multiple myeloma. The invention includes nucleic acid compositions, vector systems, modified cells, and pharmaceutical compositions that specifically target the Bob1 antigen associated with these diseases. The patent application describes how the nucleic acid composition can be used to stimulate an immune response in individuals with hyperproliferative diseases, and the modified cells can be human cells. The application also includes methods for generating the binding protein and isolated nucleic acid sequences for therapeutic use. [Extracted from the article]
Copyright of Cancer Gene Therapy Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Researchers Submit Patent Application, "T Cell Receptors Directed Against Bob1 And Uses Thereof", for Approval (USPTO 20240009235).
|
---|---|
Zeitschrift: | Cancer Gene Therapy Week, 2024-01-29, S. 153-153 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1543-6837 (print) |
Schlagwort: |
|
Sonstiges: |
|